Schizophrenia is a serious mental disease with high incidence， high disability rate and high mortality. A growing body of research has found that the glycolipid metabolism disorder in schizophrenia is related to sleep disorders， and the pathological and physiological mechanisms are not yet clear. At present， research suggests that sleep disorders， as a common clinical symptom in patients with schizophrenia， may affect the occurrence and development of glycolipid metabolism disorders in schizophrenia through the neuroendocrine system， intestinal microbiota， and other factors. The paper focuses on summarizing the research progress of schizophrenia with glycolipid metabolism disorders from four aspects， including insomnia， central disorder of hypersomnolence， circadian sleep-wake disorder， and obstructive sleep apnea， providing new recommendations for the prevention and treatment of cardiovascular diseases in patients with schizophrenia.